Sage/Biogen See Big Potential Market For Zuranolone In PPD

SKYLARK Meets Primary, Key Secondary Endpoints

Sage and Biogen announced results of the Phase III SKYLARK trial of zuranolone in postpartum depression • Source: Shutterstock

More from Strategy

More from Business